Additionally, the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway—a central regulator of antioxidant responses—is often overexpressed in RCC and is under investigation as a therapeutic target [37]. Here, NFE2L2 is linked to renal cell adenocarcinoma.